Search

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Helping pets after a natural disaster in the Carolinas

Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program

Reducing Stress in Horses – With Music

Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".

Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US

Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.

3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage

Boehringer Ingelheim and Junior Achievement: A decade of inspiring futures

Boehringer Ingelheim celebrates its decade-long partnership and volunteering milestone.

Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.

Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Boehringer Ingelheim welcomes the new guidance issued by American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Asociación Latinoamericana de Tórax for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis • K

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

Business Resource Groups at Boehringer Ingelheim

Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.

Making Toys for Shelter Animals | Boehringer Ingelheim US

Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.

From Finance to Pharma

Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo.

Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

Boehringer inhalers now available at $35 a month for eligible patients

Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients

Identifying Risk Factors to Improve Outcomes in Chronic Kidney Disease

Clinical Trials

Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

Boehringer Ingelheim Fremont, Inc.

Fremont, California, is the home of Boehringer Ingelheim’s rapidly growing US Biopharmaceuticals Business Unit

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers